• Medical_Professionals
• Medical_students
• Nurses

Most articles reporting cross-national comparison (CNC) of drug utilization (DU) data focus on reporting of outcomes. Method sections generally contain little information about data sources, data management, bias control, etc.,. Furthermore, discussion sections rarely contain in depth considerations of limitations of data sources. We must be aware that studies attempting CNC of DU data are particularly prone to systematic biases which could seriously jeopardize the validity of the comparison.  In a collaborative effort of EuroDURG, WHO Collaborating Centre of Utrecht University and a grant from ISPE, we developed a methodology to assess the validity of CNC studies. This work resulted in a Good Practice Guideline for designing, conducting, reporting and reviewing CNC studies.

Aims

To demonstrate the problems encountered while comparing DU data of different countries

To give a global overview of the CNC guideline

To focus on sources of bias in designing a CNC study

To focus on sources of bias in conducting a CNC study

Description

In a general introduction, using a large range of published CNC studies, methodological pitfalls that have jeopardized the comparison will be demonstrated. It will be shown that all problems encountered are mapped and discussed while developing a CNC methodology. The results of this common effort, the CNC guidelines will be globally presented. Then we will focus first on the sources of bias in designing a CNC study and second on the sources of bias in conducting a CNC study. Different published examples will be presented and the published information will be used to evaluate possible biases using a CNC checklist, developed for this purpose.

Bjoern Wettermark, Sweden

Pic Bruce Guthrie

Bruce Guthrie, UK

Chris Robertson, Scotland

Chris Robertson, UK

Jane Robertson, Denmark

Jane Robertson, UK

Janet Krska, England

Janet Krska, UK

Maria Matuz, Hungary

Maria Matuz, Hungary

Margaret Ryan, Scotland

Margaret Ryan, UK

Nicky Britten, England

Nicky Britten, UK

Peter Mol, The Netherlands

Peter Mol, The Netherlands

Petra Denig, The Netherlands

Petra Denig, The Netherlands

Sean MacBride-Stewart, Scotland

Seán MacBride-Stewart, UK

Rachel Bruce, Scotland

Rachel Bruce, UK

Simon Hurding, Scotland

Simon Hurding, UK

Stephen Campbell, England

Stephen Campbell, UK

Stijn Van de Velde, Norway

Veronika Wirtz, USA

Veronika Wirtz, USA

Yared Santa Ana-Tellez, Spain

Yared Santa Ana-Tellez, Spain/Mexico

Ylva Boettiger, Sweden

Ylva Boettiger, Sweden

Alison Strath, UK

Anna Birna Almarsdottir, Denmark

Antti Tanskanen, Finland

Carlos Duran, Belgium/Ecuador

Claudia Garcia Serpa Osorio-de-Castro, Brazil

Fatima Suleman, South Africa

Gabriel Sanfélix-Gimeno, Spain

Helga Gardarsdottir, The Netherlands

Lisa Pont, Australia

Robert Vander Stichele, Belgium

Thomas Balkizas, UK

Thomas Cars, Sweden

Monique Elseviers, Belgium

Emma Aarnio, Finland

Mikael Hoffmann, Sweden

Rolf Groenwold, The Netherlands

Marion Bennie, UK

GBP

Group registrations not allowed

Accompanying persons not allowed

We don’t accept Online Abstracts

Submission Info

Abstract submission deadline 2017-08-14

EuroDURG 2017 welcomes the submission of abstracts of original scientific work in the field of Drug Utilisation Reasearch.

Abstracts should include 4 paragraphs: background, methods, results, conclusion.

The abstract body should be max 300 words, including the titles of the paragraphs above.

Please use the electronic abstract submission system. You will have the option to save your submission as a draft and complete the submission at a later stage.

In submitting an abstract all presenters agree to the following terms and conditions:

I confirm that each author/ presenter listed agrees with the content of the abstract submitted for the EuroDURG 2017 and has given permission to be listed as an author/ presenter.

Where required, I have obtained the necessary research ethics approval for the project described in the abstract submitted.

I confirm that the work described in the abstract is original scientific material, unpublished at the time of the abstract submission deadline.

I understand that if the abstract has been previously presented at an international conference I can only submit it as a poster presentation.

I have checked the accuracy of the information and referencing within this abstract.

I understand that, should my abstract be accepted for presentation, I am required to pay for registration for the EuroDURG2017 conference.

I understand that my abstract will not be published until my registration and full payment have been received.

I hereby provide permission for the EuroDURG Scientific Committee to publish my accepted abstract in the Abstract Book, on the EuroDURG 2017 Conference website.

EuroDURG Conference Secretariat

Phone: 011-353-1-648-6130

Email: EuroDURG2017@abbey.ie

EuroDURG Conference Secretariat

Phone: 011-353-1-648-6130

Email: EuroDURG2017@abbey.ie